Approximately 15% of all breast cancers are triple-negative breast cancer (TNBC), which is estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative; TNBC generally exhibits a more aggressive clinical presentation2. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.